SCHAUMBURG, Ill., Aug. 27 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched fluconazole injection in premix bags. IMS Health estimates that 2008 U.S. sales of fluconazole injection approximated $18 million. Sagent will begin marketing and shipping fluconazole bags immediately.
Sagent’s fluconazole is available in 200 mg per 100 mL and 400 mg per 200 mL premix bags and is latex and preservative free.
Fluconazole injection is the generic equivalent of Pfizer’s Diflucan(R). It is indicated for the treatment of oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and for prophylactic administration to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Fluconazole injection is approved for intravenous infusion only.
About Sagent Pharmaceuticals, Inc.
To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.
SOURCE Sagent Pharmaceuticals, Inc.
CONTACT: Investors, Ronald E. Pauli of Sagent, +1-847-908-1604; or Media,
Rebekah Noven of WeissComm Partners, +1-312-646-6293, for Sagent
Pharmaceuticals, Inc.
Web site: http://www.SagentPharma.com/
